January 14, 2015
1 min read
Save

Vyvanse may be an effective treatment for binge eating disorder

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Some dosages of lisdexamfetamine dimesylate were effective in treating patients with moderate-to-severe binge eating disorder, according to data published in JAMA Psychiatry.

Susan L. McElroy, MD, of the Research Institute at Lindner Center of HOPE in Ohio, and colleagues conducted a safety (n=259) and intention-to-treat analysis (n=255) randomized study of adults with moderate-to-severe binge eating disorders.

Patients were randomly assigned to daily lisdexamfetamine dimesylate (Vyvanse, Shire) 30 mg, 50 mg, 70 mg, or placebo in a 1:1:1:1 fashion; titrated across 3 weeks, and maintained for 8 weeks.

Eleven-week data indicated that log-transformed binge eating days per week were reduced with the 50-mg (P=.008) and 70-mg daily dosage (P<.001). However, this did not apply to lower dosages (30 mg; P=.88), compared with the placebo group.

Those administered higher dosages also demonstrated greater percentages of binge eating cessation (50 mg, 42.2%; 70 mg, 50%) compared with the placebo group (21.3%).

Safety data indicated that 1.5% of patients administered lisdexamfetamine dimesylate encountered treatment-emergent adverse events, and 3.1% discontinued treatment due to these effects. One patient in the 70-mg treatment group died of toxicology findings consistent with a methamphetamine overdose, the researchers wrote.

Furthermore, patients’ mean weight in treatment groups decreased with treatment (P<.001 for each dose vs. placebo), according to data.

“Together, these findings provide substantial preliminary evidence that lisdexamfetamine may be effective for treatment of moderate-to-severe [binge eating disorder], which is consistent with its effect on [dopamine] and norepinephrine neurotransmitters and a potential effect on abnormal eating behaviors,” the researchers concluded.

Disclosure: See the study for a full list of relevant financial disclosures.